Syst-Eur

Syst-Eur

Cardiology A trial designed to evaluate the effectiveness of isolated antihypertensive therapy in preventing cardiovascular complications in elderly Pts with isolated systolic HTN. See Antihypertensive, Calcium channel blockers, Hypertension.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
The Syst-Eur study [sup][17] enrolled 4695 patients older than 60 years with SBP 160 to 219 mmHg and DBP lower than 95 mmHg.
Systolic hypertension in Europe (Syst-Eur) trial investigators, Prognostic significance of renal function in elderly patients with isolated systolic hypertension, results from the Syst-Eur trial.
However, two studies from the 1990's, Systolic Hypertension in the Elderly (SHEP), and Systolic Hypertension in Europe (SYST-EUR), proved that high systolic blood pressure was dangerous, as well.
A metanalysis of outcome trials of 15,693 patients >65 years of age and above followed up for 3.8 years included the Systolic Hypertension in Elderly Program (SHEP) (5), Systolic Hypertension in Europe Trial (Syst-Eur) (6), Systolic Hypertension in China Trial (Syst-China) (7), European Working Party on High Blood Pressure in the Elderly (EWPHE) (8), the trial on Hypertension in Elderly Patients in Primary Care (HEP) (9), the Swedish Trial on Old Patients with Hypertension (STOP) (10), and the Medical Research Council Trials in mild hypertension (MRC) (11), and in older adults (MRC 2) (12), showed a beneficial effect of the treatment of systolic hypertension on cardiovascular outcomes.
The Systolic Hypertension-Europe (Syst-Eur) trial documented a 31% reduction in all cardiovascular end points with calcium channel blocker therapy, compared with placebo, during 2 years of follow-up in a randomized study of 4,700 patients over age 60 with ISH.
The Systolic Hypertension-Europe (Syst-Eur) trial, for example, documented a 31% reduction in all cardiovascular end points with calcium channel blocker therapy compared with placebo, during 2 years of follow-up in a randomized study of 4,700 patients over age 60 with isolated systolic hypertension.
SYST-EUR, a major clinical trial on the calcium channel blocker (CCB) nimodipine found that subjects receiving the drug experienced 42% fewer strokes and 31% fewer cardiac events.
To date, there has been no definitive evaluation of the effect of antihypertensive therapy on elderly patients' quality of life, and future studies must specifically address this issue; this is one of the objectives of the SYST-EUR trial |20~, currently in progress, for ACE-inhibitors.
(41) Sentinel studies in this population include the European Working Party on High Blood Pressure in the Elderly (EWPHPE) study, (4) the Medical Research Council trial of treatment of hypertension in older adults (MRC-2), (12) the Swedish Trial in Old Patients with Hypertension-2 (STOP-2), (22) the Study on Cognition and Prognosis in the Elderly (SCOPE), (25) the Systolic Hypertension in the Elderly Program (SHEP) study, (11) the Systolic Hypertension in Europe (Syst-Eur) study, (19) and the Systolic Hypertension in China (Syst-China) study.
Data from the Systolic Hypertension in Europe (Syst-Eur) study suggest that nighttime ambulatory blood pressure is the best prognostic indicator of cardiovascular disease.
Similarly in the Systolic Hypertension in Europe (Syst-Eur) trial, knocking the mean systolic pressure down from 174 mm Hg to under 140 mm Hg resulted in a 42% reduction in stroke, a 26% reduction in coronary disease, a 29% decline in congestive heart failure, and a cumulative cardiovascular risk reduction of 31%.
This finding, the first-ever evidence of decreased dementia risk achieved through antihypertensive therapy, came from the Systolic Hypertension in Europe (Syst-Eur) trial.